Fasting Blood Glucose and Lipid Profile Alterations Following Twelve-month Androgen Deprivation Therapy in Men with Prostate Cancer

Overview

Journal ScientificWorldJournal

Publisher Wiley

Specialty Biology

Date 2012 Nov 6

PMID 23125556

Citations 8

Authors

Hasan S Saglam

Osman Kose

Sukru Kumsar

Salih Budak

Oztug Adsan

Affiliations

Soon will be listed here.

Abstract

Purpose: In this retrospective study, we aimed to investigate the effects of androgen deprivation therapy (ADT) on blood glucose and blood cholesterol levels over a 12-month period.

Materials And Methods: Between January 2010 and June 2012, the data of 44 patients with prostate cancer who were receiving ADT were collected from a hospital database. Patients with additional malignancy or diabetes and those who had been prescribed and were currently taking cholesterol-lowering medication were excluded from the study. Data (including fasting blood glucose levels and a cholesterol profile) were collected and analysed statistically. A P value <0.05 was considered statistically significant.

Results: Twelve months after the initiation of ADT, fasting blood glucose (FBG), total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride (TG) levels changed. FBG, TC, LDL cholesterol, and TG increased significantly (P = 0.009, 0.000, 0.000, and 0.000, resp.), while HDL cholesterol decreased (P = 0.000).

Conclusion: ADT may increase FBG, TC, LDL cholesterol, and TG but decrease HDL cholesterol by the end of a year of treatment. Therefore, close followup may be needed as a consequence of one-year ADT regarding metabolic alterations.

Citing Articles

Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma.

Albuquerque C, Freitas F, Martinelli A, Lima J, Coelho R, Serrano Jr C Lipids Health Dis. 2020; 19(1):133.

PMID: 32522195 PMC: 7285573. DOI: 10.1186/s12944-020-01305-8.

Cancer Biology and Prevention in Diabetes.

Srivastava S, Goodwin J Cells. 2020; 9(6).

PMID: 32498358 PMC: 7349292. DOI: 10.3390/cells9061380.

Postoperative Fasting Blood Glucose Predicts Prognosis in Stage I-III Colorectal Cancer Patients Undergoing Resection.

Xu R, You J, Li F, Yan B Gastroenterol Res Pract. 2020; 2020:2482409.

PMID: 32382263 PMC: 7199537. DOI: 10.1155/2020/2482409.

Lipid Status During Combined Treatment in Prostate Cancer Patients.

Wolny-Rokicka E, Tukiendorf A, Wydmanski J, Ostrowska M, Zembron-Lacny A Am J Mens Health. 2019; 13(5):1557988319876488.

PMID: 31559896 PMC: 6767737. DOI: 10.1177/1557988319876488.

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Campia U, Moslehi J, Amiri-Kordestani L, Barac A, Beckman J, Chism D Circulation. 2019; 139(13):e579-e602.

PMID: 30786722 PMC: 6530491. DOI: 10.1161/CIR.0000000000000641.

References

Haffner S, Mykkanen L, Valdez R, Katz M . Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993; 77(6):1610-5. DOI: 10.1210/jcem.77.6.8263149. View

Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K . The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2004; 90(2):657-60. DOI: 10.1210/jc.2004-1611. View

Meng M, Grossfeld G, Sadetsky N, Mehta S, Lubeck D, Carroll P . Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002; 60(3 Suppl 1):7-11; discussion 11-2. DOI: 10.1016/s0090-4295(02)01560-1. View

Basaria S, Muller D, Carducci M, Egan J, Dobs A . Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006; 106(3):581-8. DOI: 10.1002/cncr.21642. View

Keating N, OMalley A, Freedland S, Smith M . Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2009; 102(1):39-46. PMC: 3107568. DOI: 10.1093/jnci/djp404. View

Seidell J, Bjorntorp P, Sjostrom L, Kvist H, SANNERSTEDT R . Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990; 39(9):897-901. DOI: 10.1016/0026-0495(90)90297-p. View

Eri L, Urdal P, Bechensteen A . Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995; 154(1):100-4. View

Pagliarulo V, Bracarda S, Eisenberger M, Mottet N, Schroder F, Sternberg C . Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2011; 61(1):11-25. PMC: 3483081. DOI: 10.1016/j.eururo.2011.08.026. View

Loblaw D, Virgo K, Nam R, Somerfield M, Ben-Josef E, Mendelson D . Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007; 25(12):1596-605. DOI: 10.1200/JCO.2006.10.1949. View

10.

Mohamedali H, Breunis H, Timilshina N, Alibhai S . Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J. 2011; 5(1):28-32. PMC: 3036752. DOI: 10.5489/cuaj.09172. View

11.

Reaven G . Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37(12):1595-607. DOI: 10.2337/diab.37.12.1595. View

12.

Smith M, Finkelstein J, McGovern F, Zietman A, Fallon M, Schoenfeld D . Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87(2):599-603. DOI: 10.1210/jcem.87.2.8299. View

13.

Hromadova M, HACIK T, Malatinsky E, Riecansky I . Alterations of lipid metabolism in men with hypotestosteronemia. Horm Metab Res. 1991; 23(8):392-4. DOI: 10.1055/s-2007-1003708. View

14.

Sharifi N, Gulley J, Dahut W . Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294(2):238-44. DOI: 10.1001/jama.294.2.238. View

15.

Smith M, Malkowicz S, Chu F, Forrest J, Sieber P, Barnette K . Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008; 26(11):1824-9. PMC: 3049948. DOI: 10.1200/JCO.2007.13.5517. View

16.

Alibhai S, Gogov S, Allibhai Z . Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006; 60(3):201-15. DOI: 10.1016/j.critrevonc.2006.06.006. View

17.

Smith J, Bennett S, Evans L, Kynaston H, Parmar M, Mason M . The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001; 86(9):4261-7. DOI: 10.1210/jcem.86.9.7851. View

18.

Haffner S, Karhapaa P, Mykkanen L, Laakso M . Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994; 43(2):212-9. DOI: 10.2337/diab.43.2.212. View

19.

Dockery F, Bulpitt C, Agarwal S, Donaldson M, Rajkumar C . Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003; 104(2):195-201. DOI: 10.1042/CS20020209. View

20.

Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K . Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia. 1992; 35(2):173-7. DOI: 10.1007/BF00402551. View